文献速递泌尿男性生殖肿瘤

大分割放疗方案治疗局限性前列腺癌的随机试验

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2017-03-15

这项多中心随机非劣效性试验纳入中危前列腺癌患者,比较常规放疗78 Gy/39次/8周与大分割放疗60 Gy/20次/4周。中位随访6.0年,5年生化临床失败无病生存率两组均为85%(HR 0.96;90% CI 0.77-1.2),≥3级晚期泌尿生殖和胃肠道毒性无显著差异。大分割放疗不劣于常规放疗且不增加晚期毒性,作者认为应考虑用于中危前列腺癌。

要点

  • 大分割放疗60 Gy/20次/4周与常规放疗78 Gy/39次/8周相比,5年生化临床失败无病生存率均为85%。
  • 大分割组109/608例 vs 常规组117/598例发生生化临床失败,多数为PSA失败。
  • 两组≥3级晚期泌尿生殖和胃肠道毒性无显著差异,大分割放疗对患者更方便。

核心结论

  • 本试验所用大分割放疗方案不劣于常规放疗,且不增加晚期毒性。
  • 大分割放疗对患者更方便,作者认为应考虑用于中危前列腺癌。

研究设计与样本

  • 多中心随机非劣效性试验,纳入中危前列腺癌患者(T1-2a、Gleason评分≤6且PSA 10.1-20 ng/mL;或T2b-2c、Gleason≤6且PSA≤20 ng/mL;或T1-2、Gleason=7且PSA≤20 ng/mL)。
  • 患者随机分配至常规放疗78 Gy/39次/8周或大分割放疗60 Gy/20次/4周,不允许联合雄激素剥夺治疗。
  • 主要终点为生化临床失败(BCF),定义为PSA失败(最低点+2)、激素干预、临床局部或远处失败或前列腺癌死亡;非劣效界值为7.5%(风险比<1.32)。

主要发现

  • 中位随访6.0年,大分割组109/608例 vs 常规组117/598例发生BCF,多数事件为PSA失败。
  • 5年BCF无病生存率两组均为85%(HR 0.96;90% CI 0.77-1.2)。
  • 大分割组前列腺癌死亡10例 vs 常规组12例。
  • 两组≥3级晚期泌尿生殖毒性和胃肠道毒性无显著差异。

临床怎么用

  • 作者认为大分割放疗(60 Gy/20次/4周)应考虑用于中危前列腺癌。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Men with localized prostate cancer often are treated with external radiotherapy (RT) over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per treatment than standard RT. We hypothesized that hypofractionation versus conventional fractionation is similar in efficacy without increased toxicity. Patients and Methods We conducted a multicenter randomized noninferiority trial in intermediate-risk prostate cancer (T1 to 2a, Gleason score ≤ 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to 2c, Gleason ≤ 6, and PSA ≤ 20 ng/mL; or T1 to 2, Gleason = 7, and PSA ≤ 20 ng/mL). Patients were allocated to conventional RT of 78 Gy in 39 fractions over 8 weeks or to hypofractionated RT of 60 Gy in 20 fractions over 4 weeks. Androgen deprivation was not permitted with therapy. The primary outcome was biochemical-clinical failure (BCF) defined by any of the following: PSA failure (nadir + 2), hormonal intervention, clinical local or distant failure, or death as a result of prostate cancer. The noninferiority margin was 7.5% (hazard ratio, < 1.32). Results Median follow-up was 6.0 years. One hundred nine of 608 patients in the hypofractionated arm versus 117 of 598 in the standard arm experienced BCF. Most of the events were PSA failures. The 5-year BCF disease-free survival was 85% in both arms (hazard ratio [short v standard], 0.96; 90% CI, 0.77 to 1.2). Ten deaths as a result of prostate cancer occurred in the short arm and 12 in the standard arm. No significant differences were detected between arms for grade ≥ 3 late genitourinary and GI toxicity. Conclusion The hypofractionated RT regimen used in this trial was not inferior to conventional RT and was not associated with increased late toxicity. Hypofractionated RT is more convenient for patients and should be considered for intermediate-risk prostate cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Catton CN, Lukka H, Gu CS, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol. 2017. PMID: 28296582. doi:10.1200/JCO.2016.71.7397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。